[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0788481T3 - Fremgangsmåde til fremstilling af levobupivacain og analoger deraf - Google Patents

Fremgangsmåde til fremstilling af levobupivacain og analoger deraf

Info

Publication number
DK0788481T3
DK0788481T3 DK95934739T DK95934739T DK0788481T3 DK 0788481 T3 DK0788481 T3 DK 0788481T3 DK 95934739 T DK95934739 T DK 95934739T DK 95934739 T DK95934739 T DK 95934739T DK 0788481 T3 DK0788481 T3 DK 0788481T3
Authority
DK
Denmark
Prior art keywords
pct
levobupivacaine
amidation
alkylation
resultant
Prior art date
Application number
DK95934739T
Other languages
English (en)
Inventor
Graham Anthony Charle Frampton
Hooshang Shahriari Zavareh
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421478A external-priority patent/GB9421478D0/en
Priority claimed from GBGB9504925.0A external-priority patent/GB9504925D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of DK0788481T3 publication Critical patent/DK0788481T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95934739T 1994-10-25 1995-10-23 Fremgangsmåde til fremstilling af levobupivacain og analoger deraf DK0788481T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9421478A GB9421478D0 (en) 1994-10-25 1994-10-25 Process and compounds
GBGB9504925.0A GB9504925D0 (en) 1995-03-10 1995-03-10 Process for preparing analgesic agents
PCT/GB1995/002514 WO1996012700A1 (en) 1994-10-25 1995-10-23 Process for preparing levobupivacaine and analogues thereof

Publications (1)

Publication Number Publication Date
DK0788481T3 true DK0788481T3 (da) 2003-12-01

Family

ID=26305864

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95934739T DK0788481T3 (da) 1994-10-25 1995-10-23 Fremgangsmåde til fremstilling af levobupivacain og analoger deraf

Country Status (12)

Country Link
US (1) US5777124A (da)
EP (1) EP0788481B1 (da)
JP (1) JP4118946B2 (da)
AT (1) ATE248148T1 (da)
AU (1) AU694569B2 (da)
CA (1) CA2200356C (da)
DE (1) DE69531624T2 (da)
DK (1) DK0788481T3 (da)
ES (1) ES2203645T3 (da)
MX (1) MX9703025A (da)
PT (1) PT788481E (da)
WO (1) WO1996012700A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003024930A1 (ja) 2001-09-10 2004-12-24 メルシャン株式会社 ピペコリン酸アミド誘導体の製造方法
BRPI0104491B8 (pt) * 2001-10-10 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2218448B1 (en) * 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
AU2005287175B2 (en) 2004-09-17 2011-12-01 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
US7683175B2 (en) * 2005-06-06 2010-03-23 Navinta, Llc Process of making optically pure L-pipecolic acid and process of making anesthetics and intermediates therefrom
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20090187024A1 (en) * 2006-04-25 2009-07-23 Dishman Pharmaceuticals And Chemicals Ltd. Ropivacaine hydrochloride anhydrate and the preparation thereof
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
KR100844336B1 (ko) 2007-01-16 2008-07-07 하나제약 주식회사 레보부피바카인 및 이의 염산염의 신규한 제조방법
AU2008347158B8 (en) * 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
ATE555094T1 (de) * 2008-01-15 2012-05-15 Pharmathen Sa Verfahren zur herstellung von pipecol-2-säure-2', 6'-xylidid als zwischenprodukt für die herstellung von lokalanästhetika
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN102558030A (zh) * 2010-12-11 2012-07-11 山东方明药业股份有限公司 1-n-(2，6-二甲基苯基)-2-哌啶甲酰胺的合成
CN103086954A (zh) * 2013-02-04 2013-05-08 山东省医药工业研究所 一种制备罗哌卡因的方法
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN103664744B (zh) * 2013-11-30 2015-07-15 山东永泰化工有限公司 一种左布比卡因的制备方法
CN104003930B (zh) * 2014-06-13 2016-06-08 山东金诃药物研究开发有限公司 一种盐酸罗哌卡因的制备方法
CN105418489A (zh) * 2016-01-22 2016-03-23 江苏宝众宝达药业有限公司 一种布比卡因的合成方法
CN106187864B (zh) * 2016-07-11 2018-11-23 江苏天和制药有限公司 一种由盐酸布比卡因制备高纯度布比卡因碱的方法
CN109438331A (zh) * 2018-09-20 2019-03-08 山东科源制药股份有限公司 一种制备罗哌卡因中间体的方法
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN111548303A (zh) * 2020-06-28 2020-08-18 山东美泰医药有限公司 一种盐酸左布比卡因的杂质及其制备和分析方法
CN112939848B (zh) * 2021-02-25 2022-07-01 浙江工业大学 一种布比卡因及其中间体(s)-2-哌啶甲酸的制备方法
AU2023264568A1 (en) 2022-05-05 2024-11-14 Pfof Llc Anesthetic nerve block and method
US12070454B1 (en) 2022-05-05 2024-08-27 Pfof Llc Anesthetic nerve block and method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6803337A (da) * 1967-03-20 1968-09-23
JPS60502054A (ja) * 1983-08-01 1985-11-28 アストラ・レケメデル・アクチボラグ Ｌ―Ｎ―ｎ―プロピルピペコリン酸―２，６―キシリダイドおよびその製造方法
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide

Also Published As

Publication number Publication date
EP0788481B1 (en) 2003-08-27
US5777124A (en) 1998-07-07
JP4118946B2 (ja) 2008-07-16
AU694569B2 (en) 1998-07-23
ES2203645T3 (es) 2004-04-16
JPH10507748A (ja) 1998-07-28
WO1996012700A1 (en) 1996-05-02
EP0788481A1 (en) 1997-08-13
DE69531624T2 (de) 2004-06-17
ATE248148T1 (de) 2003-09-15
CA2200356A1 (en) 1996-05-02
AU3704995A (en) 1996-05-15
CA2200356C (en) 2007-07-31
PT788481E (pt) 2004-01-30
MX9703025A (es) 1997-10-31
DE69531624D1 (de) 2003-10-02

Similar Documents

Publication Publication Date Title
DK0788481T3 (da) Fremgangsmåde til fremstilling af levobupivacain og analoger deraf
DE69105501D1 (de) (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
ATE431739T1 (de) Pharmazeutische zusammensetzung enthaltend stabilisierte amorphe form von donepezil hydrochlorid
DK0782569T3 (da) Racemiseringsfremgangsmåde anvendt ved fremstilling af levobupivacain og analoger deraf
YU47396A (sh) 2-acilaminopropanamini i formulacije koje ih sadrže
NO971903L (no) Krystallisering av levobupivacain og analoger derav
DK0810991T3 (da) 1-Aryl-2-acylamino-ethan-forbindelser og deres anvendelse som neurokinin- især neurokinin-1-antagonister
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ES2089993T3 (es) Procedimiento y productos intermedios para la preparacion de clorhidrato de terazosina dihidrato.
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
ATE216237T1 (de) Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade
ATE229952T1 (de) Substituierte n-methyl-n-(4-(piperidin-1-yl)-2- arylbutyl)-benzamide zur behandlung von allergischen erkrankungen
DE50003759D1 (de) Verfahren zur herstellung von n-(4,5-bis-methansulfonyl-2-methyl-benzoyl)-guanidin, hydrochlorid
DK0950052T3 (da) Fremgangsmåde til fremstilling af et tetrahydropyridin-derivat
SE0103668D0 (sv) Method for the treatment of overactive blader
DK0701556T3 (da) N-((1-(4-(4-fluorphenoxy)butyl)-4-piperidinyl)N-methylamino)-2-benzo-thiazothiazololer som klasse III-antiarrytmiske midler